ClinicalTrials.gg
Not yet recruitingNCT07911579Updated Nov 3, 2026

A Study of SYH2051 in Combination With Irinotecan Hydrochloride Liposome Injection in Subjects With Advanced Solid Tumors

A Phase 1/2 interventional study of SYH2051 and Irinotecan Hydrochloride Liposome. in Advanced Solid Tumors, sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 1/2, Interventional, and Treatment

Updated Nov 3, 2026Newly registeredGo to Updates ↓
Phase
Phase 1/2
Study type
Interventional
Enrollment
154
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a multicenter, open-label, dose-escalation and dose expansion, and cohort-expansion phase Ib/II clinical study to evaluate the safety and antitumor efficacy of SYH2051 in combination with Irinotecan Hydrochloride Liposome Injection in Patients with Advanced Solid Tumors.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. is the lead sponsor of 167 studies on the registry; 47 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Fully understand the clinical study and voluntarily sign the written ICF;
  • 2. Age ≥ 18 years;
  • 3. Have at least one according to 1.1;
  • 4. performance status score of 0 to 1;
  • 5. Have adequate organ function;
  • 6. Expected survival of at least 3 months;
  • 7. Eligible participants of must agree to use a reliable method of with their partner during the study and for at least 6 months after the last dose. Female participants of childbearing potential must have a negative blood pregnancy test within 7 days prior to the first dose;
  • 8. or cytologically confirmed diagnosis of advanced solid tumors.

Exclusion criteria

Exclusion Criteria:

  • 1. Patients with other active malignant tumors;
  • 2. Uncontrolled serous effusions requiring frequent drainage or medical intervention within 14 days prior to the first dose;
  • 3. Serious chronic or active infection;
  • 4. Surgical on vital organs within 4 weeks prior to the first dose or planned systemic or local tumor resection during the study;
  • 5. Untreated (including baseline findings) or unstable parenchymal , spinal cord metastases or compression, carcinomatous meningitis;
  • 6. History of non-infectious lung disease/pneumonitis requiring hormone therapy or current interstitial lung disease/pneumonitis or suspected by imaging during screening;
  • 7. History of significant cardiovascular disease;
  • 8. History of immunodeficiency, Active or ;
  • 9. Known serious allergic reactions to the study drug or other ingredients and in the formulation;
  • 10. Pregnant or lactating women;
  • 11. Presence of other conditions that could interfere with the participant 's participation in study procedures or would not be in the best interest of the participant' s participation in the study or affect the study results: such as a history of mental illness, drug use, or drug abuse, any other disease or condition.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
154 participants (estimated)

Study arms

  • Experimental
    SYH2051 in combination with Irinotecan Hydrochloride Liposome.

    Drug: SYH2051 · Drug: Irinotecan Hydrochloride Liposome.

Interventions

  • SYH2051 is an oral medication taken once daily, with dosage selected according to the dose group.

  • DrugIrinotecan Hydrochloride Liposome.

    Irinotecan Hydrochloride Liposome is administered by intravenous infusion every 2 weeks (Q2W)

06

What researchers measure

Primary outcomes

  1. DLT

    Time frame: From Day 1 to Day 28

  2. Frequency and severity of AE

    Time frame: From Day 1 to 12 months.

  3. Maximal tolerable dose (MTD)

    Time frame: From Day 1 to 12 months.

  4. Recommended phase 2 dose (RP2D)

    Time frame: From Day 1 to 12 months.

  5. ORR

    Time frame: From Day 1 to 12 months.

Secondary outcomes

  1. Cmax

    Time frame: From Day 1 to 12 months.

  2. AUCss,

    Time frame: From Day 1 to 12 months.

  3. ORR

    Time frame: From Day 1 to 12 months.

  4. PFS

    Time frame: From Day 1 to 12 months.

  5. OS

    Time frame: From Day 1 to 18 months.

07

Study locations

1 site
08

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07911579
Responsible party
Sponsor
First posted
Nov 3, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
Dec 30, 2028 (estimated)
Completion
Dec 30, 2029 (estimated)
Last update
Nov 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ATM Inhibitor SYH2051

Start the discussion